ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML Post author:admERY Post published:January 15, 2014 Post category:Newsroom ERYTECH announces it received authorizations for its Phase IIb GRASPA-ML clinical trial in Acute Myeloid Leukemia (AML) in Finland and Spain. You Might Also Like ERYTECH announces plans to conduct registered initial public offering in the United States July 28, 2015 ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar April 28, 2022 ERYTECH to Host Third Quarter 2017 Conference Call and Business Update on November 14, 2017 November 13, 2017
ERYTECH announces plans to conduct registered initial public offering in the United States July 28, 2015
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar April 28, 2022
ERYTECH to Host Third Quarter 2017 Conference Call and Business Update on November 14, 2017 November 13, 2017